Search results for: Innovation Policy Prize
Filter search results
Multi-indication Pricing: Pros, Cons and Applicability to the UK
1 October 2015
Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. As value is likely to differ across major indications, if prices paid for on-patent…
Dementia: The R&D Landscape
1 November 2015
This OHE Research Paper provides an overview of the current dementia R&D landscape. The research was undertaken by OHE for Imperial College and the UK Department of Health. This OHE…
Data Governance Arrangements for Real-World Evidence
1 November 2015
The objective of this OHE Consulting Report was to understand and develop a view on the core principles that should govern how Real-World Data (RWD) is accessed or generated, and…
Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism
30 March 2023
Share this: Download publication Simon Brassel Isobel Firth Edward Oliver Grace Hampson Adrian Towse Lotte Steuten In this report, we describe the design of a globally aligned, value-based, fully-delinked pull…
Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS
1 August 2018
This OHE Consulting Report reviews “Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS.” The project was funded by the ABPI. For the year 2015/16, the Treasury reported…
Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward
1 December 2018
This report provides a detailed summary of a panel discussion held at the HTAi 2017 annual meeting in Rome on the current approaches to MIP in Europe, the perceived challenges,…
Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?
1 May 2019
Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as a way to better…
Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?
1 June 2019
Cada vez más, los avances científicos desarrollan nuevas medicinas que permiten mejoras en la supervivencia y calidad de vida para diversas indicaciones terapéuticas. La fijación de precios en función de…
Data Governance Arrangements for Real-World Evidence in Japan
1 September 2019
In 2015, OHE Consulting published a report on data governance arrangements for real-world evidence (RWE) covering the specifics under which RWE was used in eight different countries: Australia, France, Germany,…